| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein—polysaccharide conjugate vaccines and immunological reagents
|
Lees, Andrew
|
|
1996
|
14 |
3 |
p. 190-198
9 p.
|
article
|
| 2 |
Adjuvant properties of non-phospholipid liposomes (Novasomes®) in experimental animals for human vaccine antigens
|
Gupta, Rajesh K.
|
|
1996
|
14 |
3 |
p. 219-225
7 p.
|
article
|
| 3 |
Calendar
|
|
|
1996
|
14 |
3 |
p. 250-
1 p.
|
article
|
| 4 |
Five year follow-up of morbidity and mortality among recipients of high-titre measles vaccines in Senegal
|
Aaby, Peter
|
|
1996
|
14 |
3 |
p. 226-229
4 p.
|
article
|
| 5 |
Immunization coverage required to prevent outbreaks of dog rabies
|
Coleman, Paul G.
|
|
1996
|
14 |
3 |
p. 185-186
2 p.
|
article
|
| 6 |
Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru
|
Lanata, Claudio F.
|
|
1996
|
14 |
3 |
p. 237-243
7 p.
|
article
|
| 7 |
Influence of chicken genotype on protection against Marek's disease by a herpesvirus of turkeys recombinant expressing the glycoprotein B (gB) of Marek's disease virus
|
Ross, N.
|
|
1996
|
14 |
3 |
p. 187-189
3 p.
|
article
|
| 8 |
International Scientific Conference on Viral Safety and Evaluation of Viral Clearance from Biopharmaceutical Products
|
Sanhueza, Sonia
|
|
1996
|
14 |
3 |
p. 244-246
3 p.
|
article
|
| 9 |
Longitudinal study of an epitope-biased serum haemagglutination-inhibition antibody response in rabbits immunized with type A influenza virions
|
Lambkin, R.
|
|
1996
|
14 |
3 |
p. 212-218
7 p.
|
article
|
| 10 |
New metazoan parasite antigens; recombinant protein antigen production and anti-idiotypic antibody, for vector expression in host cell and transgenic animal, for application in recombinant vaccine production
|
|
|
1996
|
14 |
3 |
p. 248-
1 p.
|
article
|
| 11 |
New recombinant Chlamydia trachomatis PGP3 protein; recombinant vaccine and therapeutic production by vector expression in Escherichia coli
|
|
|
1996
|
14 |
3 |
p. 248-249
2 p.
|
article
|
| 12 |
Nucleic acid sequence from Barbary duck parvo virus; and related vectors, transformed cells, proteins, etc., useful as diagnostic and in protective vaccine
|
|
|
1996
|
14 |
3 |
p. 248-
1 p.
|
article
|
| 13 |
Parenteral vaccination of mice and piglets with F4+ Escherichia coli suppresses the enteric anti-F4 response upon oral infection
|
Bianchi, A.T.J.
|
|
1996
|
14 |
3 |
p. 199-206
8 p.
|
article
|
| 14 |
Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs)
|
Tarpey, Ian
|
|
1996
|
14 |
3 |
p. 230-236
7 p.
|
article
|
| 15 |
Production of viral particles; retrovirus e.g. HIV virus-1 particle production and purification using T-lymphocyte lymphoma cell culture in serum-free culture for use in a vaccine
|
|
|
1996
|
14 |
3 |
p. 248-
1 p.
|
article
|
| 16 |
Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children
|
Raz, Raul
|
|
1996
|
14 |
3 |
p. 207-211
5 p.
|
article
|
| 17 |
Three to four instead of one millilitre of formalin
|
Ebisawa, Isao
|
|
1996
|
14 |
3 |
p. 247-
1 p.
|
article
|
| 18 |
Virulence-attenuated virus encoding an HIV and/or CTL antigen; vaccinia virus or canary-pox virus vector with an HIV virus-1 or cytotoxic T-lymphocyte antigen, for use as a recombinant vaccine
|
|
|
1996
|
14 |
3 |
p. 248-
1 p.
|
article
|
Journal description